Shots:
- Biohaven & Merus have entered into a research collaboration & license agreement to co-develop bispecific ADCs using the former’s ADC conjugation & payload platform plus Merus’ Biclonics tech platform
- As per the terms, Biohaven will develop preclinical ADCs for 3 Merus’ BsAbs (2 developed via Biclonics & 1 in preclinical) & each is eligible for advancement through mutual agreement, with shared development costs & commercialization
- Merus will get an upfront & license fee on the nomination of 1st ADC program plus will handle the BsAb development cost while Biohaven will fund the ADC generation
Ref: Merus| Image: Merus & Biohaven
Related News:- Merus Collaborates with Partner Therapeutics to Commercialize Zenocutuzumab for Treating NRG1 Fusion-Positive Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
